Ionis Pharmaceuticals, Inc.
$74.84
▲
0.08%
2026-04-22 10:12:13
www.ionis.com
NMS: IONS
Explore Ionis Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$12.38 B
Current Price
$74.84
52W High / Low
$86.74 / $27.9
Stock P/E
—
Book Value
$3
Dividend Yield
—
ROCE
-13.92%
ROE
-70.8%
Face Value
—
EPS
$-2.38
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
1,402
Beta
0.4
Debt / Equity
534.84
Current Ratio
3.83
Quick Ratio
3.81
Forward P/E
-120.83
Price / Sales
13.16
Enterprise Value
$12.35 B
EV / EBITDA
-33.45
EV / Revenue
13.09
Rating
Buy
Target Price
$96.81
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Calidi Biotherapeutics, Inc. | $0.25 | — | $3 M | — | -410.2% | -7.01% | $19.2 / $0.21 | $0.51 |
| 2. | Spyre Therapeutics, Inc. | $73.39 | — | $5.76 B | — | -30.53% | -25.17% | $75 / $12.25 | $7.16 |
| 3. | Arvinas, Inc. | $10.81 | — | $703.57 M | — | -20.59% | -16.23% | $14.51 / $5.9 | $6.83 |
| 4. | TuHURA Biosciences, Inc. | $2.83 | — | $179.93 M | 0% | -120.19% | -1.69% | $4.44 / $0.41 | $0.35 |
| 5. | Adial Pharmaceuticals, Inc. | $1.63 | — | $2.33 M | — | -147.82% | -1.71% | $687.5 / $1.54 | $4.75 |
| 6. | Avalo Therapeutics, Inc. | $14.66 | — | $334.08 M | — | -70.45% | -72.44% | $20.72 / $3.39 | $4.49 |
| 7. | Ocugen, Inc. | $1.85 | — | $606.61 M | — | -307.31% | -7.77% | $2.73 / $0.64 | $-0.04 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 203.33 M | 156.72 M | 452.05 M | 131.61 M | 226.58 M | — |
| Operating Profit | -214.47 M | -160.17 M | 139.84 M | -146.95 M | -110.84 M | — |
| Net Profit | -229.39 M | -128.61 M | 123.55 M | -146.94 M | -104.35 M | — |
| EPS in Rs | -1.39 | -0.78 | 0.75 | -0.89 | -0.63 | -0.95 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 943.71 M | 705.14 M | 787.65 M | 587.37 M |
| Operating Profit | -381.72 M | -475.11 M | -353.73 M | -410.19 M |
| Net Profit | -381.39 M | -453.9 M | -366.29 M | -269.72 M |
| EPS in Rs | -2.31 | -2.75 | -2.22 | -1.63 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 3.52 B | 3 B | 2.99 B | 2.53 B |
| Total Liabilities | 3.03 B | 2.42 B | 2.6 B | 1.96 B |
| Equity | 489.09 M | 588.35 M | 386.69 M | 572.89 M |
| Current Assets | 2.99 B | 2.62 B | 2.64 B | 2.2 B |
| Current Liabilities | 781.57 M | 309.32 M | 448.09 M | 311.56 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -268.58 M | -500.95 M | -307.51 M | -274.37 M |
| Investing CF | -277.78 M | -134.03 M | -214.13 M | -262.64 M |
| Financing CF | 675.84 M | 478.06 M | 644.08 M | -55.3 M |
| Free CF | -325.67 M | -551.29 M | -335.5 M | -294.47 M |
| Capex | -57.08 M | -50.34 M | -27.99 M | -20.1 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -10.48% | 34.1% | — | — |
| Earnings Growth % | -23.92% | -35.8% | — | — |
| Profit Margin % | -64.37% | -46.5% | -45.92% | — |
| Operating Margin % | -67.38% | -44.91% | -69.84% | — |
| Gross Margin % | 98.41% | 98.84% | 97.6% | — |
| EBITDA Margin % | -50.16% | -29.2% | -38.78% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.